Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Richardson, Paul G. | - |
dc.contributor.author | Hungria, Vania T. M. | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Beksac, Meral | - |
dc.contributor.author | Dimopoulos, Meletios Athanasios | - |
dc.contributor.author | Elghandour, Ashraf | - |
dc.contributor.author | Jedrzejczak, Wieslaw W. | - |
dc.contributor.author | Guenther, Andreas | - |
dc.contributor.author | Nakorn, Thanyaphong Na | - |
dc.contributor.author | Siritanaratkul, Noppadol | - |
dc.contributor.author | Schlossman, Robert L. | - |
dc.contributor.author | Hou, Jian | - |
dc.contributor.author | Moreau, Philippe | - |
dc.contributor.author | Lonial, Sagar | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Einsele, Hermann | - |
dc.contributor.author | Sopala, Monika | - |
dc.contributor.author | Bengoudifa, Bourras-Rezki | - |
dc.contributor.author | Corrado, Claudia | - |
dc.contributor.author | Binlich, Florence | - |
dc.contributor.author | San-Miguel, Jesus F. | - |
dc.date.available | 2020-02-28T02:45:23Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-02-11 | - |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8572 | - |
dc.description.abstract | Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) led to a significant increase in progression-free survival (PFS) vs placebo plus bortezomib and dexamethasone (Pbo-BTZ-Dex) in patients with relapsed or relapsed and refractory MM in the phase 3PANORAMA1 trial. This subgroup analysis evaluated outcomes in patients in the PANORAMA 1 trial based on prior treatment: a prior immunomodulatory drug (IMiD; n = 485), prior bortezomib plus an IMiD (n = 193), and >= 2 prior regimens including bortezomib and an IMiD (n = 147). Median PFS with PAN-BTZ-Dex vs Pbo-BTZ-Dex across subgroups was as follows: prior IMiD (12.3 vs 7.4 months; hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.43-0.68), prior bortezomib plus IMiD (10.6 vs 5.8 months; HR, 0.52; 95% CI, 0.36-0.76), and >= 2 prior regimens including bortezomib and an IMiD (12.5 vs 4.7 months; HR, 0.47; 95% CI, 0.31-0.72). Common grade 3/4 adverse events and laboratory abnormalities in patients who received PAN-BTZ-Dex across the prior treatment groups included thrombocytopenia, lymphopenia, neutropenia, diarrhea, and asthenia/fatigue. Incidence of on-treatment deaths among patients who received prior bortezomib and an IMiD (regardless of number of prior regimens) was similar between treatment arms. This analysis demonstrated a clear PFS benefit of 7.8 months with PAN-BTZ-Dex among patients who received >= 2 prior regimens including bortezomib and an IMiD, a population with limited treatment options and poorer prognosis. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC HEMATOLOGY | - |
dc.relation.isPartOf | BLOOD | - |
dc.subject | REFRACTORY MYELOMA | - |
dc.subject | QUALITY | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | COMBINATION | - |
dc.subject | MULTICENTER | - |
dc.subject | CARFILZOMIB | - |
dc.subject | SURVIVAL | - |
dc.subject | PHASE-2 | - |
dc.subject | IMPACT | - |
dc.subject | RISK | - |
dc.title | Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000373394600012 | - |
dc.identifier.doi | 10.1182/blood-2015-09-665018 | - |
dc.identifier.bibliographicCitation | BLOOD, v.127, no.6, pp.713 - 721 | - |
dc.identifier.scopusid | 2-s2.0-84959357825 | - |
dc.citation.endPage | 721 | - |
dc.citation.startPage | 713 | - |
dc.citation.title | BLOOD | - |
dc.citation.volume | 127 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | REFRACTORY MYELOMA | - |
dc.subject.keywordPlus | QUALITY | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | CARFILZOMIB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | PHASE-2 | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.